Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 plus Bevacizumab in recurrent glioblastoma
NCT01582152Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2012
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
A Phase 2 trial of abeotaxane in glioblastoma (GBM), Gliosarcoma (GS), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2012; status: terminated.
02
Drugs
abeotaxane
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01582152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582152.